REHOVOT, Israel, Sept. 1, 2020 /PRNewswire/ — Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a number one computational biology firm centered on revolutionizing product discovery and improvement in a number of life-science primarily based industries, together with human well being and agriculture, in the present day introduced that it has entered right into a definitive settlement with ARK Funding Administration, LLC (ARK Make investments) and Alpha Capital Anstalt in reference to a registered direct providing of peculiar shares at a value per share of $1.70, for an mixture money consideration of $10 million. Of the mixture funding quantity, ARK Make investments, a number one expertise funding agency, specializing in thematic investing in disruptive innovation, will make investments $7 million and Alpha Capital Anstalt will make investments $Three million.
Evogene intends to make use of the online proceeds from the providing to additional develop its and its subsidiaries’ product pipelines, to additional improve and develop its computational predictive biology platform, and for working capital and normal company functions.
The providing is predicted to shut on or earlier than September 3, 2020, topic to customary closing circumstances.
The shares of frequent inventory supplied within the registered direct providing described above are being supplied by Evogene pursuant to its shelf registration assertion on Type F-3 (File No.333-240249) beforehand filed and declared efficient by the Securities and Trade Fee (the “SEC”) on August 10, 2020. The providing could also be made solely by the use of a prospectus complement and accompanying prospectus. A ultimate prospectus complement and accompanying prospectus regarding the providing will likely be filed with the SEC and will likely be out there on the SEC’s web site.
This press launch is for informational functions solely and shouldn’t be construed as funding recommendation and doesn’t represent a proposal to promote or the solicitation of a proposal to purchase these securities, nor will there be any sale of those securities in any state or different jurisdiction wherein such supply, solicitation or sale could be illegal previous to registration or qualification underneath the securities legal guidelines of any such state or jurisdiction.
About Evogene Ltd.:
Evogene (NASDAQ: EVGN, TASE: EVGN.TA) is a number one computational biology firm centered on revolutionizing product discovery and improvement in a number of life-science primarily based industries, together with human well being and agriculture, by way of the usage of its broadly relevant Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged by way of the facility of Large Knowledge and Synthetic Intelligence, has been designed to computationally uncover and uniquely information the event of life-science merchandise primarily based on microbes, small molecules and genetic components. Using the CPB platform, Evogene and its subsidiaries at the moment are advancing product pipelines for human microbiome-based therapeutics by way of Biomica Ltd., medical hashish by way of Canonic Ltd., ag-biologicals by way of Lavie Bio Ltd., ag-chemicals by way of AgPlenus Ltd., and ag-solutions for castor oil manufacturing by way of Casterra Ltd. For extra info, please go to www.evogene.com
About ARK Make investments:
Headquartered in New York Metropolis, ARK Funding Administration LLC is a federally registered funding adviser with the U.S. Securities and Trade Fee and privately held funding agency. Specializing in thematic investing in disruptive innovation, the agency is rooted in over 40 years of expertise in figuring out and investing in improvements that ought to change the way in which the world works. By way of its open analysis course of, ARK identifies firms that it believes are main and benefiting from cross-sector improvements comparable to robotics, vitality storage, DNA sequencing, synthetic intelligence, and blockchain expertise.
ARK’s funding methods embrace: Autonomous Expertise and Robotics, Subsequent Era Web, Genomic Revolution, Fintech Improvements, 3D Printing, Israel Revolutionary Expertise, and the general ARK Disruptive Innovation Technique. For extra info, please go to www.ark-invest.com
Ahead Wanting Statements:
This press launch comprises “forward-looking statements” regarding future occasions. These statements could also be recognized by phrases comparable to “could”, “might”, “expects”, “intends”, “anticipates”, “plans”, “believes”, “scheduled”, “estimates”, or phrases of comparable which means. For instance, Evogene is utilizing forward-looking assertion on this press launch when it discusses the meant use of proceeds and shutting of the registered direct providing. Such statements are primarily based on present expectations, estimates, projections and assumptions, describe opinions about future occasions, and contain sure dangers and uncertainties that are tough to foretell and usually are not ensures of future efficiency. Subsequently, precise future outcomes, efficiency or achievements of Evogene and its subsidiaries could differ materially from what’s expressed or implied by such forward-looking statements as a result of quite a lot of elements, lots of that are past the management of Evogene and its subsidiaries, together with, with out limitation, the worldwide unfold of COVID-19, or the Coronavirus, the varied restrictions deriving therefrom and people threat elements contained in Evogene’s studies filed with the relevant securities authorities. As well as, Evogene and its subsidiaries rely, and count on to proceed to rely, on third events to conduct sure actions, comparable to their field-trials and pre-clinical research, and if these third events don’t efficiently perform their contractual duties, adjust to regulatory necessities or meet anticipated deadlines (together with on account of the impact of the Coronavirus), Evogene and its subsidiaries could expertise important delays within the conduct of their actions. Evogene and its subsidiaries disclaim any obligation or dedication to replace these forward-looking statements to replicate future occasions or developments or adjustments in expectations, estimates, projections and assumptions.